Centers of Excellence in Regulatory Science and Innovation (CERSIs)
Supports Multi cooperative agreements funding university FDA research partnerships on FDA's regulatory science priorities.
The Centers of Excellence in Regulatory Science and Innovation, or CERSIs, are FDA cooperative agreements under the Office of Regulatory and Emerging Science. They sit above the individual project level and fund long-term university partnerships that advance regulatory science research, training, scholar awards, and workshops aligned with FDA's regulatory science priorities. Current awards started on September 1, 2023, with a maximum of $50 million over five years for each center. The active portfolio includes five centers: the University of Maryland, Johns Hopkins University, UCSF-Stanford, Yale-Mayo Clinic, and Research Triangle CERSI. Those awards run through approximately 2028 under RFA-FD-23-004, so no new competition is expected until the current cycle ends. The record also notes that each center runs sub-grant programs that can be reached by external researchers. This route is aimed at universities and academic medical centers that can lead a large regulatory-science consortium and sustain a multi-year federal partnership. It suits institutions with strong FDA-facing research depth, the administrative capacity to manage a cooperative agreement, and the ability to build downstream opportunities for scholars and external collaborators through center-run subprograms.
No upcoming rounds verified. Cadence: One-off.